Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of
patients worldwide. Despite all the efforts to understand its pathogenesis and develop new …

Autoimmune disorders occur when immune cells go wrong and attack the body's own
tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive …

With the promise of a potentially “single dose curative” paradigm, CAR‐T cell therapies have
brought a paradigm shift in the treatment and management of hematological malignancies …

Chimeric antigen receptor (CAR) technology, and CAR-T cells in particular, have emerged
as a new and powerful tool in cancer immunotherapy since demonstrating efficacy against …

Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most
patients, as persistent clonal evolution drives new mutations which confer MM high-risk …

Relapsed/refractory multiple myeloma remains a challenging disease necessitating the
development of more effective treatment options. In the past decade, myeloma therapies …

Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …

With the gradual improvement of treatment regimens, the survival time of multiple myeloma
(MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an …

Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is
approved in the United States and Europe for patients with relapsed/refractory multiple …

Autologous patient‐derived adoptive T‐cell therapies have revolutionized the management
of relapsed multiple myeloma (MM). However, the current manufacturing and quality control …